Who are Paracetamol hot drink's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, Metamizole Sodium, Ibuprofen plus Omeprazole, Motrin and narcotic, Topical NSAID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paracetamol-hot-drink.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paracetamol hot drink — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paracetamol hot drink (Paracetamol hot drink) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic. Area: Pain management.

phase 2 Non-opioid analgesic COX-2 Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Paracetamol hot drink (Paracetamol hot drink) — GlaxoSmithKline. Paracetamol acts as an inhibitor of COX-2 enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paracetamol hot drink TARGET	Paracetamol hot drink	GlaxoSmithKline	phase 2	Non-opioid analgesic	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Metamizole Sodium	Metamizole Sodium	Insel Gruppe AG, University Hospital Bern	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Ibuprofen plus Omeprazole	Ibuprofen plus Omeprazole	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	NSAID plus proton pump inhibitor combination	COX-1/COX-2 (ibuprofen); H+/K+-ATPase (omeprazole)
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)
Topical NSAID	Topical NSAID	University of Nottingham	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (Non-opioid analgesic class)

Allodynic Therapeutics, Inc · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
Muhammad Rahman Efendi Nasution · 1 drug in this class
Nevakar, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paracetamol hot drink — Competitive Intelligence Brief. https://druglandscape.com/ci/paracetamol-hot-drink. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab